Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 838-844

  Stephans, Kevin L ^a,b   Djemil, Toufik ^a   Reddy, Chandana A ^a   Gajdos, Stephen M ^a   Kolar, Mathew ^a   Machuzak, Michael ^b   Mazzone, Peter ^a   Videtic, Gregory M M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Medically inoperable; Pulmonary function; Stage I lung cancer; Stereotactic body radiation

Indexed keywords

CARBON MONOXIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CAUSE OF DEATH; CLINICAL ASSESSMENT; COMORBIDITY; COMPARATIVE STUDY; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; HEART DISEASE; HUMAN; LUNG CANCER; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; SAFETY; STEREOTACTIC BODY RADIATION THERAPY; THERAPY EFFECT; TOTAL LUNG CAPACITY;

EID: 68549123565     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a99ff6     Document Type: Article

References (30)

1. Smythe WR. Treatment of stage I non-small cell lung carcinoma. Chest 2003;123:181S-187S. (Pubitemid 36135716)
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392. (Pubitemid 38101633)
3. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2002;121:1155-1158. (Pubitemid 34280436)
4. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer 2006;51:97-103. (Pubitemid 43088629)
5. Paludan M, Traberg Hansen A, Petersen J, Grau C, Høyer M. Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: is there a dose-volume dependency? Acta Oncol 2006;45:818-822. (Pubitemid 44423127)
6. Sibley GS. Radiotherapy for patients with medically inoperable stage Inonsmall cell lung carcinoma: smaller volumes and higher doses-a review. Cancer 1998;82:433-438.
7. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I doseescalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005;103: 2118-2127. (Pubitemid 40605120)
8. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-S100. (Pubitemid 47183602)
9. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006;45:787-795. (Pubitemid 44423123)
10. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005;63:1010-1015. (Pubitemid 41505277)
11. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-1431. (Pubitemid 41628038)
12. Ng AW, Tung SY, Wong VY. Hypofractionated stereotactic radiotherapy for medically inoperable stage I non-small cell lung cancer-report on clinical outcome and dose to critical organs. Radiother Oncol 2008; 87:24-28.
13. Onimaru R, Fujino M, Yamazaki K, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:374-381.
14. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-4839. (Pubitemid 46630909)
15. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-1955. (Pubitemid 37433596)
16. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670. (Pubitemid 32951783)
17. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2006;66:117-125. (Pubitemid 44175645)
18. Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 2006;45:796-801. (Pubitemid 44423124)
19. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007;2:21.
20. Timmerman R, Paulas R, Galvin J, et al. Toxicity analysis of RTOG 0236 using stereotactic body radiation therapy to treat medically inoperable early stage lung cancer patients. Int J Radiat Oncol Biol Phys 2007;69:S86.
21. Henderson M, McGarry R, Yiannoutsos C, et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;72:404-409.
22. Ohashi T, Takeda A, Shigematsu N, et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys 2005;62:1003-1008. (Pubitemid 40884410)
23. Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 2003;56:126-135. (Pubitemid 36403684)
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383. (Pubitemid 17055592)
25. Radiation Therapy Oncology Group. http://www.rtog.org/members/ protocols/0236/0236.pdf. Accessed April 6, 2009.
26. Bucci M, Chang J, McAleer M, et al. Pulmonary function tests before and after stereotactic radiation of the lung. Int J Radiat Oncol Biol Phys 2007;69:S510. (Pubitemid 46862947)
27. Pratt D, El Naqa J, Bradley J. Pulmonary function testing after stereotactic body radiation therapy for medically inoperable patients with early stage NSCLC. Int J Radiat Oncol Biol Phys 2007;S516-S517.
28. Bradley J. Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2007;2:S118-S124. (Pubitemid 47183606)
29. Puri S, Baker BL, Dutka DP, Oakley CM, Hughes JM, Cleland JG. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation 1995;91:2769-2774.
30. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285:1441-1446.